Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) EBIT (2024 - 2025)

Historic EBIT for Kura Oncology (KURA) over the last 2 years, with Q3 2025 value amounting to -$80.0 million.

  • Kura Oncology's EBIT fell 3358.66% to -$80.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$239.8 million, marking a year-over-year change of. This contributed to the annual value of -$193.2 million for FY2024, which is 1652.01% down from last year.
  • As of Q3 2025, Kura Oncology's EBIT stood at -$80.0 million, which was down 3358.66% from -$72.7 million recorded in Q2 2025.
  • Over the past 5 years, Kura Oncology's EBIT peaked at -$22.5 million during Q4 2024, and registered a low of -$80.0 million during Q3 2025.